Asthma

Asthma as a Chronic Inflammatory Airway Disorder

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction, bronchial hyperresponsiveness, and respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough. It affects approximately 7.8% of the U.S. population and remains a leading cause of emergency department visits and hospitalizations among adults.^[1] For the Family Nurse Practitioner (FNP) managing adult and geriatric patients, recognition of asthma mimics (e.g., COPD, heart failure, vocal cord dysfunction) and age-specific treatment modifications are critical for safe, evidence-based care.

This guide is organized around current Global Initiative for Asthma (GINA) and National Asthma Education and Prevention Program (NAEPP) guidelines, with emphasis on high-yield exam concepts for FNP certification.^[2][3]

Airway Inflammation, Hyperresponsiveness, and Reversibility

Defining Asthma

• Asthma – A heterogeneous disease characterized by chronic airway inflammation, variable expiratory airflow limitation, and symptoms that change over time and in intensity.^[2]
• Airway hyperresponsiveness – An exaggerated bronchoconstrictor response to a variety of stimuli (allergens, exercise, cold air, irritants).
• Reversibility – Improvement in forced expiratory volume in 1 second (FEV₁) of ≥12% and ≥200 mL after bronchodilator administration (or after 4 weeks of anti-inflammatory therapy).^[3]

Asthma Pathophysiology (At a Glance)

• Early-phase response: IgE-mediated mast cell degranulation → histamine, leukotrienes, prostaglandins → smooth muscle spasm, edema, mucus secretion.
• Late-phase response: Eosinophil and neutrophil infiltration, epithelial shedding, mucus plugging, airway remodeling.
• Key structural changes: Subepithelial fibrosis, smooth muscle hypertrophy, goblet cell hyperplasia, increased vascularity.

Diagnostic Approach and Severity Classification

Stepwise Diagnosis in Adults and Older Adults

1. Clinical history – Recurrent episodes of wheeze, dyspnea, chest tightness, cough (often worse at night or with triggers).
2. Spirometry – Initial test to document airflow limitation (FEV₁/FVC ratio < 0.70) and bronchodilator reversibility.
3. Bronchial challenge testing – If spirometry is normal but symptoms suggest asthma; methacholine challenge is the test of choice.
4. Peak expiratory flow (PEF) monitoring – Diurnal variability > 10% (or > 20% in more severe cases) supports diagnosis.
5. Consider alternative diagnoses – Especially in patients > 40 years: COPD, asthma-COPD overlap (ACO), congestive heart failure, pulmonary embolism, vocal cord dysfunction, medication-induced cough (ACE inhibitors).

Asthma Classification

Note: GINA 2024 de-emphasizes severity classification and advocates for an “assess–adjust–review” treatment cycle.^[2]

Clinical Manifestations and Age-Related Variations

Common Clinical Presentation

• Wheezing – High-pitched expiratory sound; may become biphasic in severe attacks.
• Dyspnea – Often worse with exertion, cold air, or allergen exposure.
• Chest tightness – Described as a “band around the chest.”
• Cough – May be the only symptom (cough-variant asthma); dry or productive of clear mucus.
• Use of accessory muscles – Indicates moderate-to-severe obstruction.
• Prolonged expiratory phase – On auscultation.

Atypical Findings in Older Adults (Age ≥ 65)

• Less likely to report wheeze; more likely to present with dyspnea on exertion that mimics COPD or heart failure.
• Reduced perception of bronchoconstriction → delayed presentation.
• Higher prevalence of comorbid conditions (GERD, obesity, allergic rhinitis) that worsen asthma control.^[4]
• Increased risk of adverse effects from medications (e.g., beta-blockers, NSAIDs, ACE inhibitors).

Objective Testing and Exacerbation Recognition

Objective Testing

• Spirometry – Essential for confirming diagnosis; measure FEV₁, FVC, FEV₁/FVC ratio. A post-bronchodilator FEV₁ increase of ≥12% and ≥200 mL confirms asthma.^[3]
• Fractional exhaled nitric oxide (FeNO) – Elevated levels (> 50 ppb) correlate with eosinophilic inflammation; useful for monitoring adherence to inhaled corticosteroids.^[5]
• Allergy testing – Skin prick or specific IgE (RAST) for common aeroallergens; helps identify triggers.
• Assessment of severity/control: Use validated tools such as Asthma Control Test (ACT) or GINA symptom questionnaire.^[2]

Recognizing a Severe Exacerbation (Status Asthmaticus)

• Inability to speak in full sentences, respiratory rate > 30, tachycardia (> 120 bpm), pulsus paradoxus, use of sternocleidomastoid muscles, silent chest (ominous sign).
• Peak expiratory flow < 40% of personal best or < 30–50% predicted.
• Oxygen saturation < 90% on room air.

Pharmacologic Stepwise Therapy and Acute Care

Stepwise Pharmacologic Management (Adults & Geriatrics)

General principles: Inhaled corticosteroids (ICS) are the cornerstone of asthma control. The “preferred” stepwise approach per GINA 2024 is outlined below.^[2]

1. Step 1: As-needed low-dose ICS-formoterol (alone or with SABA) – now widely adopted for mild asthma.
2. Step 2: Regular low-dose ICS plus as-needed SABA (or as-needed ICS-formoterol).
3. Step 3: Low-dose ICS-LABA (e.g., budesonide-formoterol, fluticasone-salmeterol).
4. Step 4: Medium-dose ICS-LABA.
5. Step 5: High-dose ICS-LABA + add-on therapy: consider long-acting muscarinic antagonist (LAMA), oral corticosteroids (lowest possible dose), or biologic agents (dupilumab, omalizumab, mepolizumab, benralizumab).

Geriatric considerations: Use large-volume spacers to improve inhaler technique; avoid anticholinergics in patients with narrow-angle glaucoma or prostatic hypertrophy; monitor for osteoporosis with long-term oral corticosteroids.^[4]

Patient Education & Self-Management

• Inhaler technique – Assess at every visit. Mist steps are among the most common causes of poor control.
• Written asthma action plan – Including green/yellow/red zones based on PEF or symptoms.
• Avoidance of triggers – Allergens, tobacco smoke, NSAIDs (if aspirin-exacerbated respiratory disease), beta-blockers.
• Vaccinations – Annual influenza vaccine; pneumococcal vaccine per CDC guidelines.^[6]

Acute Exacerbation Management (Urgent Care/ED)

• Bronchodilators: Inhaled short-acting beta-agonists (SABA) q20min ×3 doses initially; continuous nebulized SABA for severe cases.
• Systemic corticosteroids: Prednisone 40–60 mg/day (oral) or methylprednisolone IV for severe attacks – taper not usually required if duration < 1 week.
• Supplemental oxygen – Titrate SpO₂ to ≥ 90%.
• Magnesium sulfate – Consider IV for severe exacerbations not responding to initial therapy.^[7]
• Heliox & noninvasive ventilation – May be used in refractory cases; avoid mechanical intubation if possible.

Medication Safety and Complication Prevention

Drug Safety and Interactions

• Black box warning: Long-acting beta-agonists (LABAs) should not be used as monotherapy; must be combined with ICS.^[3]
• NSAID sensitivity – Ask about aspirin/naproxen-induced asthma attacks; avoid in aspirin-exacerbated respiratory disease (AERD).
• Selective beta-blockers – Even low-dose cardioselective beta-blockers can worsen bronchospasm; use extreme caution.
• Oral corticosteroids in older adults – Increased risk of hyperglycemia, osteoporosis, cataracts, infection.

Complications from Poorly Controlled Asthma

• Status asthmaticus – Life-threatening respiratory failure requiring intensive care.
• Airway remodeling – Irreversible decline in lung function over years.
• Side effects of chronic therapy – Oral thrush (ICS), hoarseness, adrenal suppression (high-dose ICS).
• Psychosocial impact – Anxiety, depression, reduced quality of life.

Red Flags in the Older Adult

• Progressive dyspnea without wheezing → consider heart failure or pulmonary fibrosis.
• Hemoptysis → evaluate for bronchiectasis or lung cancer.
• Sudden-onset severe airway obstruction with stridor → consider vocal cord dysfunction or anaphylaxis.

Critical Clinical Nuances for FNP Certification

• Classic testable fact: The hallmark of asthma is reversible airflow obstruction – this is what separates it from COPD.
• GINA 2024 shift: SABA-only therapy is no longer recommended for any step (even Step 1). Expect this on FNP exams.^[2]
• Mnemonic for risk factors: “A WHEEZE” – Allergens/Atopy, Weather (cold air), Hormones (menses), Exercise, Emotions, Exposures (tobacco, NSAIDs, beta-blockers), Environment (workplace), and (G) GERD.
• Peak flow zones: Green > 80% personal best; Yellow 50–80%; Red < 50% – instruct patient to seek immediate care.
• Biologics: Omalizumab (anti-IgE) for allergic asthma; mepolizumab, benralizumab (anti-IL-5) for eosinophilic asthma; dupilumab (anti-IL-4/IL-13) for severe asthma with type 2 inflammation.
• Pregnancy: Uncontrolled asthma is more dangerous for the fetus than asthma medications – continue ICS, preferred budesonide (Pregnancy Category B).^[8]
• Older adults: Always assess for polypharmacy, inhaler technique, and cognitive ability to adhere to action plan.

References & Sources

1. Centers for Disease Control and Prevention. Asthma Surveillance Data. 2023. https://www.cdc.gov/asthma/most_recent_data.htm
2. Global Initiative for Asthma. GINA Report: Global Strategy for Asthma Management and Prevention. 2024 Update. https://ginasthma.org/gina-reports/
3. National Heart, Lung, and Blood Institute (NHLBI). Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. 2007 (Updated 2020). https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma
4. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. https://doi.org/10.1164/rccm.9120-11ST
5. Lewis SL, Dirksen SR, Heitkemper MM, Bucher L. Medical-Surgical Nursing: Assessment and Management of Clinical Problems. 11th ed. Elsevier; 2021. https://www.researchgate.net/publication/336967864_Lewis%27_medical-surgical_nursing_Assessment_and_management_of_clinical_problems_11th_ed